Two experimental drugs for the treatment of MDR TB have completed phase II clinical trials.

Bangalore, February 8, 2012: Avesthagen Limited – India’s leading sytems biology biotechnology company, has signed a MOU with CosmosID™, a U.S. based company for collaborating to correctly diagnose and therapeutically manage Tuberculosis treatment.

A team from Stellenbosch University's Desmond Tutu TB Centre will be monitoring 200 children at the Brooklyn Chest Hospital in Cape Town over the next five years in a potentially groundbreaking trial.

The Bill & Melinda Gates Foundation today announced $7.7 million in funding for 10 new grants to identify biomarkers for diagnosing tuberculosis (TB) in low-resource settings.

The management of tuberculosis cases in the European Union (EU) is not meeting international standards, according to new research.

Health officials and workers are concerned about budget shortages for the treatment of tuberculosis in the Kingdom as new data reveals that prevalence of the disease has declined 37 percent from 2002, officials said yesterday.

A significant proportion - about 15% to 20% - of all tuberculosis (TB) occurs in children in India, where paediatric TB is a serious, but under-recognized and neglected public health problem.

PHNOM PENH, Feb. 8 (Xinhua) -- The tuberculosis prevalence rate in Cambodia has seen a 36 percent decline in the last decade, according to a new survey released on Wednesday.

The United States has given Vietnam new equipment to help speed up the diagnosis of a drug resistant strain of tuberculosis.

On January 6, 2012, the FDA announced that the package insert for efavirenz has been updated to include a new dosing recommendation for HIV-infected patients with tuberculosis (TB): When efavirenz is coadministered with rifampin in patients weighing 50 kg, it should be dosed at 800 mg once daily instead of the usual 600 mg daily. The evidence cited to support this recommendation is from drug–drug interaction trials and a pharmacokinetic modeling study. These studies suggest that coadministration reduces systemic exposure to efavirenz when that drug is given at 600 mg daily, but not when it is given at 800 mg daily; at the higher dose, systemic exposure is comparable to that achieved when efavirenz is dosed at 600 mg daily without rifampin.